SCHEMBL13359331

SCHEMBL13359331

CCCCCCCCC(CCCCCCCCC=O)C(CCCCCCCC)CCCCCCCCC(=O)OC

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
EPHX2 P34913 1/20 0.50
TSHR P16473 1/20 0.48
POLB P06746 1/20 0.46
POLA1 P09884 1/20 0.46
DGKA P23743 1/20 0.46
PPARG P37231 1/20 0.45
FAAH O00519 2/20 0.44
TRPV1 Q8NER1 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 1/20 0.44
PRKCE Q02156 1/20 0.44
PRKCQ Q04759 1/20 0.44
PRKCD Q05655 1/20 0.44
PRKCA P17252 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Decanal SCHEMBL7730841 0.91 ALDH1A1 (0.59) ALDH1A1LMNAEPHX2TSHRPOLB
Palmitaldehyde SCHEMBL7730843 0.91 ALDH1A1 (0.59) ALDH1A1LMNAEPHX2TSHRPOLB
SCHEMBL14947259 0.89 LMNA (0.53) ALDH1A1LMNAEPHX2TSHRPOLB
SCHEMBL14947261 0.89 LMNA (0.53) ALDH1A1LMNAEPHX2TSHRPOLB
SCHEMBL8812283 0.83 LMNA (0.68) ALDH1A1LMNAEPHX2TSHRPOLB
SCHEMBL7201423 0.83 LMNA (0.68) ALDH1A1LMNAEPHX2TSHRPOLB
SCHEMBL1976573 0.83 LMNA (0.68) ALDH1A1LMNAEPHX2TSHRPOLB
SCHEMBL8814164 0.83 LMNA (0.68) ALDH1A1LMNAEPHX2TSHRPOLB
SCHEMBL8441499 0.83 LMNA (0.68) ALDH1A1LMNAEPHX2TSHRPOLB
SCHEMBL436881 0.83 LMNA (0.68) ALDH1A1LMNAEPHX2TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714040-B2 Phase change inks containing curable amide gellant compounds XEROX CORPORATION (US) 2010-05-11 US disclosed
US-7276614-B2 Curable amide gellant compounds XEROX CORPORATION (US) 2007-10-02 US disclosed
US-7271284-B2 Process for making curable amide gellant compounds XEROX CORPORATION (US) 2007-09-18 US disclosed
US-7259275-B2 Method for preparing curable amide gellant compounds XEROX CORPORATION (US) 2007-08-21 US disclosed
US-20070123606-A1 Phase change inks containing curable amide gellant compounds XEROX CORPORATION 2007-05-31 US disclosed
US-20070123724-A1 Method for preparing curable amide gellant compounds XEROX CORPORATION 2007-05-31 US disclosed
US-20070123663-A1 Process for making curable amide gellant compounds XEROX CORPORATION 2007-05-31 US disclosed
US-20070123722-A1 Ester-terminated oligoamides and polyamides having terminal ethylenic double bonds; gelling agents for phase change ink jet inks with improved ultraviolet curability and solubility XEROX CORPORATION 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123724-A1 Method for preparing curable amide gellant compounds ODC1, INO80C, AOC1 ALDH1A1 526/4885LMNA 1024/4885EPHX2 89/4885
US-20070123722-A1 Ester-terminated oligoamides and polyamides having terminal ethylenic double bonds; gelling agents for phase change ink jet inks with improved ultraviolet curability and solubility CCNA2, ELL, CCNA1 ALDH1A1 1908/4885LMNA 1260/4885EPHX2 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.